Adriawan IR, Atschekzei F, Dittrich-Breiholz O, Garantziotis P, Hirsch S, Risser LM, Kosanke M, Schmidt RE, Witte T, Sogkas G (2022) Novel aspects of regulatory T cell dysfunction as a therapeutic target in giant cell arteritis. Ann Rheum Dis 81(1):124–131. https://doi.org/10.1136/annrheumdis-2021-220955

Article  CAS  PubMed  Google Scholar 

Attarian S (2024) New treatment strategies in myasthenia gravis. Rev Neurol (Paris) 180(9):971–981. https://doi.org/10.1016/j.neurol.2024.09.006

Article  CAS  PubMed  Google Scholar 

Barnett C, Tabasinejad R, Bril V (2019) Current pharmacotherapeutic options for myasthenia gravis. Expert Opin Pharmacother 20(18):2295–2303. https://doi.org/10.1080/14656566.2019.1682548

Article  CAS  PubMed  Google Scholar 

Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB (2015) Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells. J Autoimmun 56:66–80. https://doi.org/10.1016/j.jaut.2014.10.002

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castaño D, Wang S, Atencio-Garcia S, Shields EJ, Rico MC, Sharpe H, Bustamante J, Feng A, Le Coz C, Romberg N, Tobias JW, Utz PJ, Henrickson SE, Casanova JL, Bonasio R, Locci M (2024) IL-12 drives the differentiation of human T follicular regulatory cells. Sci Immunol 9(97):eadf2047. https://doi.org/10.1126/sciimmunol.adf2047

Article  CAS  PubMed  Google Scholar 

Cavalcante P, Bernasconi P, Mantegazza R (2012) Autoimmune mechanisms in myasthenia gravis. Curr Opin Neurol 25(5):621–629. https://doi.org/10.1097/WCO.0b013e328357a829

Article  CAS  PubMed  Google Scholar 

Çebi M, Çakar A, Durmuş H, Akan O, Aysal F, Parman Y, Saruhan-Direskeneli G (2024) In vitro modulation of T cells in myasthenia gravis by low-dose IL-2. Eur J Immunol 54(11):e2451268. https://doi.org/10.1002/eji.202451268

Article  CAS  PubMed  Google Scholar 

Cebi M, Cakar A, Erdogdu E, Durmus-Tekce H, Yegen G, Ozkan B, Parman Y, Saruhan-Direskeneli G (2023) Thymoma patients with or without myasthenia gravis have increased Th17 cells, IL-17 production and ICOS expression. J Neuroimmunol 381:578129. https://doi.org/10.1016/j.jneuroim.2023.578129

Article  CAS  PubMed  Google Scholar 

Chen P, Tang X (2021) Gut microbiota as regulators of Th17/Treg balance in patients with myasthenia gravis. Front Immunol 12:803101. https://doi.org/10.3389/fimmu.2021.803101

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Zhang XS, Wang YG, Lu C, Li J, Zhang P (2021) Imbalance of Th17 and Tregs in thymoma may be a pathological mechanism of myasthenia gravis. Mol Immunol 133:67–76. https://doi.org/10.1016/j.molimm.2021.02.011

Article  CAS  PubMed  Google Scholar 

Chung JB, Brudno JN, Borie D, Kochenderfer JN (2024) Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol 24(11):830–845. https://doi.org/10.1038/s41577-024-01035-3

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dikiy S, Li J, Bai L, Jiang M, Janke L, Zong X, Hao X, Hoyos B, Wang ZM, Xu B, Fan Y, Rudensky AY, Feng Y (2021) A distal Foxp3 enhancer enables interleukin-2 dependent thymic Treg cell lineage commitment for robust immune tolerance. Immunity 54(5):931–946.e911. https://doi.org/10.1016/j.immuni.2021.03.020

Article  CAS  PubMed  PubMed Central  Google Scholar 

Engebretsen I, Gilhus NE, Kristiansen IS, Sæther EM, Lindberg-Schager I, Arneberg F, Bugge C (2024) The epidemiology and societal costs of myasthenia gravis in Norway: a non-interventional study using national registry data. Eur J Neurol 31(5):e16233. https://doi.org/10.1111/ene.16233

Article  PubMed  PubMed Central  Google Scholar 

Franke A, Dahl S, Funck M, Bakker H, Garbers C, Lokau J (2025) Interleukin-2 receptor α (IL-2Rα/CD25) shedding is differentially regulated by N- and O-glycosylation. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1872(1):119863. https://doi.org/10.1016/j.bbamcr.2024.119863

Article  CAS  PubMed  Google Scholar 

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren J (2019) Myasthenia gravis. Nat Rev Dis Primers 5(1):30. https://doi.org/10.1038/s41572-019-0079-y

Article  PubMed  Google Scholar 

Graßhoff H, Comdühr S, Monne LR, Müller A, Lamprecht P, Riemekasten G, Humrich JY (2021) Low-Dose IL-2 therapy in autoimmune and rheumatic diseases. Front Immunol 12:648408. https://doi.org/10.3389/fimmu.2021.648408

Article  CAS  PubMed  PubMed Central  Google Scholar 

Haghikia A, Schett G, Mougiakakos D (2024) B cell-targeting chimeric antigen receptor T cells as an emerging therapy in neuroimmunological diseases. Lancet Neurol 23(6):615–624. https://doi.org/10.1016/s1474-4422(24)00140-6

Article  CAS  PubMed  Google Scholar 

He J, Chen J, Miao M, Zhang R, Cheng G, Wang Y, Feng R, Huang B, Luan H, Jia Y, Jin Y, Zhang X, Shao M, Wang Y, Zhang X, Li J, Zhao X, Wang H, Liu T, Xiao Xian, Su Yin, Mu Rong, Ye Hua, Li Ru, Liu Xu, Liu Yanying, Li Chun, Liu Huixin, Hu Fanlei, Guo Jianping, Liu Wanli, Zhang Wen-Bin, Jacob Alexander, Ambrus Julian L. Jr, Ding Changhai, Yu Di, Sun Xiaolin, Li Zhanguo (2022) Efficacy and safety of low-dose interleukin 2 for primary Sjögren syndrome: a randomized clinical trial. JAMA Netw Open 5(11):e2241451. https://doi.org/10.1001/jamanetworkopen.2022.41451

Hernandez R, Põder J, LaPorte KM, Malek TR (2022) Engineering IL-2 for immunotherapy of autoimmunity and cancer. Nat Rev Immunol 22(10):614–628. https://doi.org/10.1038/s41577-022-00680-w

Article  CAS  PubMed  Google Scholar 

Howard JF Jr., Bril V, Vu T, Karam C, Peric S, Margania T, Murai H, Bilinska M, Shakarishvili R, Smilowski M, Guglietta A, Ulrichts P, Vangeneugden T, Utsugisawa K, Verschuuren J, Mantegazza R (2021) Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 20(7):526–536. https://doi.org/10.1016/s1474-4422(21)00159-9

Huang H, Ran H, Liu X, Yu L, Qiu L, Lin Z, Ou C, Lu Y, Yang W, Liu W (2021) Leflunomide ameliorates experimental autoimmune myasthenia gravis by regulating humoral and cellular immune responses. Int Immunopharmacol 93:107434. https://doi.org/10.1016/j.intimp.2021.107434

Article  CAS  PubMed  Google Scholar 

Humrich JY, Cacoub P, Rosenzwajg M, Pitoiset F, Pham HP, Guidoux J, Leroux D, Vazquez T, Riemekasten G, Smolen JS, Tsokos G, Klatzmann D (2022) Low-dose interleukin-2 therapy in active systemic lupus erythematosus (LUPIL-2): a multicentre, double-blind, randomised and placebo-controlled phase II trial. Ann Rheum Dis 81(12):1685–1694. https://doi.org/10.1136/ard-2022-222501

Article  CAS  PubMed  Google Scholar 

Ingelfinger F, Krishnarajah S, Kramer M, Utz SG, Galli E, Lutz M, Zwicky P, Akarca AU, Jurado NP, Ulutekin C, Bamert D, Widmer CC, Piccoli L, Sallusto F, Núñez NG, Marafioti T, Schneiter D, Opitz I, Lanzavecchia A, Jung Hans H., De Feo Donatella, Mundt Sarah, Schreiner Bettina, Becher Burkhard (2021) Single-cell profiling of myasthenia gravis identifies a pathogenic T cell signature. Acta Neuropathol 141(6):901–915. https://doi.org/10.1007/s00401-021-02299-y

Article  CAS  PubMed  PubMed Central  Google Scholar 

Iorio R (2024) Myasthenia gravis: the changing treatment landscape in the era of molecular therapies. Nat Rev Neurol 20(2):84–98. https://doi.org/10.1038/s41582-023-00916-w

Article  CAS  PubMed  Google Scholar 

Janelle V, Delisle JS (2021) T-cell dysfunction as a limitation of adoptive immunotherapy: current concepts and mitigation strategies. Cancers (Basel). https://doi.org/10.3390/cancers13040598

Article  PubMed  Google Scholar 

Johnston RJ, Choi YS, Diamond JA, Yang JA, Crotty S (2012) STAT5 is a potent negative regulator of TFH cell differentiation. J Exp Med 209(2):243–250. https://doi.org/10.1084/jem.20111174

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawajiri A, Li J, Koinuma K, Yang Z, Yoon HJ, Yi J, Nagashima H, Ishii M, Gao F, Sato K, Tayama S, Harigae H, Iwakura Y, Ishii N, Sher A, Ishigaki K, Zhu J, Kim KS, Kawabe T (2024) Naturally arising memory-phenotype CD4(+) T lymphocytes contain an undifferentiated population that can generate T(H)1, T(H)17, and T(reg) cells. Sci Adv 10(49):eadq6618. https://doi.org/10.1126/sciadv.adq6618

Article  CAS  PubMed  PubMed Central